Page last updated: 2024-09-05

deferasirox and Adenocarcinoma, Basal Cell

deferasirox has been researched along with Adenocarcinoma, Basal Cell in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Assayag, F; Becette, V; Bièche, I; Bonin, F; Callens, C; Caly, M; Chateau-Joubert, S; de la Grange, P; Gentien, D; Lallemand, F; Marangoni, E; Rapinat, A; Schnitzler, A; Servely, JL; Tury, S; Vacher, S1
Bedford, MR; Ford, SJ; Iqbal, T; Pang, W; Tselepis, C; Tucker, O; Wood, A1

Other Studies

2 other study(ies) available for deferasirox and Adenocarcinoma, Basal Cell

ArticleYear
The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
    The Journal of pathology, 2018, Volume: 246, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carboplatin; Cell Proliferation; Cisplatin; Deferasirox; Doxorubicin; Drug Synergism; Humans; Iron; Iron Chelating Agents; MCF-7 Cells; Mice, Nude; NF-kappa B; Phosphatidylinositol 3-Kinase; Signal Transduction; Time Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2018
A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.
    Annals of the Royal College of Surgeons of England, 2014, Volume: 96, Issue:4

    Topics: Adenocarcinoma; Aged; Anemia, Iron-Deficiency; Benzoates; Chelation Therapy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deferasirox; Esophageal Neoplasms; Esophagectomy; Female; Ferritins; Hemoglobins; Humans; Iron; Iron Chelating Agents; Male; Patient Selection; Prospective Studies; Triazoles

2014
chemdatabank.com